María Paula Montoya

María Paula Montoya

Auto-generated profile, based on publicly available information

María Paula Montoya

Cancer and Molecular Medicine Research Group - CAMMO, Bogotá, D. C., Colombia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2024 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
JBJheremy Sebastian Reyes Barreto
Jheremy Sebastian Reyes Barreto
LJLeidy Viviana Giron Jurado
Leidy Viviana Giron Jurado
MEMaria Paula Montoya Estrada
Maria Paula Montoya Estrada
IMIris Lorena Sánchez Moreno
Iris Lorena Sánchez Moreno
LMLaura Tatiana Picón Moncada
Laura Tatiana Picón Moncada
LFLibia Adriana Gaona Fernández
Libia Adriana Gaona Fernández
Multiple Myeloma (MM) is the second most common hematological malignancy and one of the 19 most frequent types of cancer. Its diagnosis is a challenge due to the low rate of disease recognition, and diagnosis delays lead to the characteristic end-organ damage of the disease. New approaches to tackle that diagnosis challenge are required. Emerging evidence shows that Piwi-interacting RNAs (piRNA) promote increased methylation in MM cells. In this analysis, we delve into the latest discoveries surrounding piRNA biogenesis and functions, offering fresh perspectives on the possible uses of piRNAs in detection and diagnosis in MM. piRNA-823 increases in MM cells and positively correlates with the disease stage. Its tumorigenic actions in MM relate to intercellular communication between MM and vein endothelial cells. These findings provide the necessary information to highlight the possible role of piRNA-823 as a biomarker for MM diagnosis.

10 December 2025 in Biomédica
Verified
Journal Article
Open access
PDF file
JRJheremy Sebastián Reyes
Jheremy Sebastián Reyes
JGJhonathan David Guevara
Jhonathan David Guevara
LPLaura Tatiana Picón
Laura Tatiana Picón
ISIris Lorena Sánchez
Iris Lorena Sánchez
LGLibia Andrea Gaona
Libia Andrea Gaona
LPLuis Eduardo Pino
Luis Eduardo Pino
Introduction. PIWI-interacting RNAs are small and non-coding RNAs involved in gene regulation and transposable element repression, emerging as critical biomarkers and therapeutic targets in oncology. Advances in artificial intelligence, such as recurrent neural networks, long short-term memory networks, and graph convolutional networks, offer significant improvements in PIWI-interacting RNA detection.Objectives. To evaluate the performance of artificial intelligence models, including recurrent neural networks, long short-term memory, and graph convolutional networks, in detecting PIWI-interacting RNAs and assessing their implications for cancer diagnostics and prognosis.Materials and methods. A systematic review of 24 studies was conducted across PubMed, ScienceDirect, Scopus, and Web of Science, focusing on artificial intelligence-based approaches for PIWI-interacting RNA detection. Inclusion criteria were original articles published in English or Spanish using artificial intelligence models in clinical or experimental settings. Performance metrics such as accuracy, sensitivity, and specificity were analyzed.Results. Long short-term memory models achieved the highest overall accuracy (92.3%), followed by graph convolutional networks (91.4%), support vector machines (88%), and recurrent neural networks (85.7%). Sensitivity and specificity were also highest in long short-term memory (94% and 91%, respectively). Graph convolutional networks showed superior performance in identifying PIWI-interacting RNA-disease associations with complex datasets. Support vector machine models were effective in smaller datasets but exhibited scalability limitations.Conclusion. Artificial intelligence models, especially long short-term memory and graph convolutional networks, significantly enhance PIWI-interacting RNA detection, supporting their application in cancer diagnostics and personalized medicine. Future studies should refine these models, address dataset biases, and explore their integration into clinical workflows.

22 June 2024 in Revista Nova publicación científica en ciencias biomédicas
Verified
Journal Article
Open access
MMMaría Paula Montoya
María Paula Montoya
GRGloria Julieth Rincón
Gloria Julieth Rincón
Julian E. MuñozJulian E. Muñoz
Julian E. Muñoz
SOSharon Hassbleidy Ochoa
Sharon Hassbleidy Ochoa
CCClaudia Andrea Cruz
Claudia Andrea Cruz
JNJeanette Navarrete
Jeanette Navarrete
Introduction: Myeloperoxidase (MPO) is an antimicrobial protein present in the azuro- philic granules of neutrophils, its action falls when it is conjugated in the phagosome with hydrogen peroxide, resulting in toxic substances for phagocytosed microorganisms. Seve- ral authors have described that recurrent vulvovaginal infections by Candida spp., are rela- ted to primary MPO deficiency, which is an autosomal recessive disorder, due to polymor- phisms associated with posttranslational processing or pre-translational errors. Objective: To identify the relationship between the two MPO polymorphisms (Y173C-M251T) with a higher probability of presenting vulvovaginal infection. Materials and methods: 27 blood samples were collected from women between 20-45 years old diagnosed with vul- vovaginal candidiasis in order to analyze the complete blood count, Wright stain, leuko- cyte peroxidase stain and perform DNA extraction to assess the quantity and quality of genetic material. Subsequently, primers for the mpo gene were designed by bioinformatic tools and the conditions to standardize conventional PCR were established. Amplified products were sequenced by capillary electrophoresis (CES) to identify polymorphisms. Results: The polymorphisms of interest were not found in any sample. However, nucleoti- de changes were found in exons 4 and 6 of the fragment studied in two samples analyzed, indicating that this region may present genetic variability. Conclusion: The present study is a first approximation in Colombia on the mpo gene polymorphisms from patients with vulvovaginal Candidiasis in Bogotá D.C. Future studies with a more representative num- ber of samples will give us stronger indications of the genetic variability that the mpo gene may present.